Titan Medical Inc.
TSX VENTURE : TMD
OTCQX : TITXF

Titan Medical Inc.

September 09, 2014 07:00 ET

Titan Medical Inc. Appoints Dr. Dennis Fowler as Executive Vice President, Clinical and Regulatory Affairs

TORONTO, ONTARIO--(Marketwired - Sept. 9, 2014) - Titan Medical Inc. ("Titan" or the "Company") (TSX VENTURE:TMD)(OTCQX:TITXF) today announced that Dr. Dennis Fowler, who currently serves as the Company's Director of Clinical Affairs, has been appointed to the newly-created position of Executive Vice President, Clinical and Regulatory Affairs.

In his new role, Dr. Fowler will be responsible for all of Titan's clinical and regulatory affairs, including pre-clinical testing and clinical development. He will also oversee Titan's U.S. and international regulatory pathways for the Company's Single Port Orifice Robotic Technology (SPORT™) Surgical System. He will work closely with the clinical and regulatory departments of Ximedica, a premier product development firm for the medical industry partnered with Titan.

"Dr. Fowler has made invaluable contributions to the development of our technology. He has led the surgical advisory boards of several companies that successfully commercialized significant healthcare products," said John Hargrove, Chief Executive Officer of Titan. "We are excited to have someone with his demonstrated technical expertise, experience and leadership skills guiding our clinical and regulatory efforts as we continue the development of SPORT™."

Dr. Fowler commented, "I am very pleased to be part of the Titan team and look forward to continuing to contribute to the development and commercialization of the SPORT™ Surgical System."

Dr. Fowler has been Director of Clinical Affairs at Titan since September 2013. Prior to that, he was a consultant to the Company. He is a co-inventor of the single-incision Insertable Robotic Effector Platform (IREP) technology, which was licensed from Columbia University for use in Titan's SPORT™ Surgical System.

Formerly, he was the Gerald and Janet Carrus Professor of Surgical Science and Director of the Center for Innovation and Outcomes Research in the Department of Surgery, Columbia University College of Physicians and Surgeons. Among other former positions, he was V.P.-Medical Director of Perioperative Services at New York Presbyterian Hospital/Columbia. In addition to his clinical, research, teaching, and administrative responsibilities, he has been the recipient of numerous honors and is a well-established author of many scientific publications.

Dr. Fowler received his M.D. in 1973 from the University of Kansas School of Medicine and received his Master of Public Health in 2008 from Columbia University, Mailman School of Public Health. He is certified by the American Board of Surgery and is a Fellow and former Governor-at-Large of the American College of Surgeons. He has held numerous leadership positions and roles in the Society of American Gastrointestinal and Endoscopic Surgeons (SAGES), the Fellowship Council, the American Board of Surgery, and is currently President of the Foundation for Surgical Fellowships.

About Titan Medical Inc.

Titan Medical Inc. is a Canadian public company focused on the design and development of a robotic surgical system for application in minimally invasive surgery ("MIS"). The Company's Single Port Orifice Robotic Technology, SPORT™ Surgical System, currently under development, is comprised of a surgeon-controlled robotic platform that includes a 3D vision system and interactive instruments for performing MIS procedures, and a surgeon workstation that provides the surgeon with an interface to the robotic platform for controlling the interactive instruments and providing a 3D endoscopic view of inside a patient's body during MIS procedures. The SPORT™ Surgical System is being designed to expand robotic surgery into both simple and complex areas of surgical specialties and procedures that are currently under-serviced. It is also being designed to allow surgeons to perform procedures within small- to medium-size surgical spaces, such as general surgery and cholecystectomy. For more information, visit the Company's website at www.titanmedicalinc.com.

About Ximedica

Ximedica is a full service ISO 13485 certified and FDA registered product development firm with an exclusive focus on medical products. With more than 25 years of experience developing medical devices, combination products and consumer healthcare, Ximedica's client base spans the globe and ranges from start-ups to the world's largest medical device manufacturers. Ximedica's mission is to create products that meet international regulatory requirements and strategic business goals. For more information, visit the Company's website at http://www.ximedica.com.

Forward-Looking Statements

This news release contains "forward-looking statements" which reflect the current expectations of management of the Company's future growth, results of operations, performance and business prospects and opportunities. Wherever possible, words such as "may", "would", "could", "will", "anticipate", "believe", "plan", "expect", "intend", "estimate", "potential for" and similar expressions have been used to identify these forward-looking statements. These statements reflect management's current beliefs with respect to future events and are based on information currently available to management. Forward-looking statements involve significant risks, uncertainties and assumptions. Many factors could cause the Company's actual results, performance or achievements to be materially different from any future results, performance or achievements that may be expressed or implied by such forward-looking statements, including, without limitation, those listed in the "Risk Factors " section of the Company's Annual Information Form dated April 4, 2014 (which may be viewed at www.sedar.com). Should one or more of these risks or uncertainties materialize, or should assumptions underlying the forward looking statements prove incorrect, actual results, performance or achievements may vary materially from those expressed or implied by the forward-looking statements contained in this news release. These factors should be considered carefully and prospective investors should not place undue reliance on the forward-looking statements. Although the forward-looking statements contained in the news release are based upon what management currently believes to be reasonable assumptions, the Company cannot assure prospective investors that actual results, performance or achievements will be consistent with these forward-looking statements.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Contact Information